Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OYST

Oyster Point Pharma (OYST) Stock Price, News & Analysis

Oyster Point Pharma logo

About Oyster Point Pharma Stock (NASDAQ:OYST)

Advanced Chart

Key Stats

Today's Range
$11.17
$11.17
50-Day Range
$11.08
$11.20
52-Week Range
$3.46
$19.00
Volume
330 shs
Average Volume
212,171 shs
Market Capitalization
$299.85 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Receive OYST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oyster Point Pharma and its competitors with MarketBeat's FREE daily newsletter.

OYST Stock News Headlines

Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they gotten away with it, the Fed and U.S. banks could have seized control of our financial lives forever. But Trump stopped them cold on January 23rd, 2025, when he outlawed CBDCs… Paving the way for Elon Musk's secret master plan.
See More Headlines

OYST Stock Analysis - Frequently Asked Questions

Oyster Point Pharma, Inc. (NASDAQ:OYST) announced its earnings results on Thursday, November, 4th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.48. The company had revenue of $17.94 million for the quarter. Oyster Point Pharma had a negative trailing twelve-month return on equity of 490.33% and a negative net margin of 901.99%.

Oyster Point Pharma (OYST) raised $85 million in an initial public offering on Thursday, October 31st 2019. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Cowen and Piper Jaffray served as the underwriters for the IPO.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oyster Point Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD).

Company Calendar

Last Earnings
11/04/2021
Today
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:OYST
Fax
N/A
Employees
303
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-100,660,000.00
Net Margins
-901.99%
Pretax Margin
-901.99%

Debt

Sales & Book Value

Annual Sales
$24.54 million
Price / Cash Flow
N/A
Book Value
$3.80 per share
Price / Book
2.94

Miscellaneous

Free Float
22,039,000
Market Cap
$299.85 million
Optionable
Not Optionable
Beta
1.31
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:OYST) was last updated on 5/14/2025 by MarketBeat.com Staff
From Our Partners